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Abstract
Sepsis is one of the leading causes of acute kidney injury (AKI). Septic patients who develop acute kidney injury (AKI) are at
increased risk of death. To date there is no effective treatment for AKI or septic AKI. Based on their anti-inflammatory
properties, we examined the effects of nicotinic acetylcholine receptor agonists on renal damage using a mouse model of
lipopolysaccharide (LPS)-induced AKI where localized LPS promotes inflammation-mediated kidney damage. Administration
of nicotine (1 mg/kg) or GTS-21 (4 mg/kg) significantly abrogated renal leukocyte infiltration (by 40%) and attenuated
kidney injury. These renoprotective effects were accompanied by reduced systemic and localized kidney inflammation
during LPS-induced AKI. Consistent with these observations, nicotinic agonist treatment significantly decreased renal IkBa
degradation and NFkB activation during LPS-induced AKI. Treatment of human kidney cells with nicotinic agonists, an NFkB
inhibitor (Bay11), or a proteasome inhibitor (MG132) effectively inhibited their inflammatory responses following stimulation
with LPS or TNFa. Renal proteasome activity, a major regulator of NFkB-mediated inflammation, was enhanced by
approximately 50% during LPS-induced AKI and elevated proteasome activity was significantly blunted by nicotinic agonist
administration in vivo. Taken together, our results identify enhanced renal proteasome activity during LPS-induced AKI and
the suppression of both proteasome activity and inflammation by nicotinic agonists to attenuate LPS-induced kidney injury.
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Introduction
The kidney is a frequent target for sepsis-associated multi-organ
injury, with increasing prevalence of acute kidney injury (AKI)





have overall increased morbidity, require prolonged hospital stays,
use more healthcare resources, and have increased mortality. The
pathophysiologyofsepticAKIiscomplex,multi-factorialanddistinct
from non-septic AKI [2–5]. Epidemiological, clinical, and experi-
mentalstudiessupporttheconceptthatpro-inflammatorymediators
produced during sepsis promote intrarenal hemodynamic changes,
endothelial dysfunction, leukocyte infiltration, and damaging tissue
inflammationthatleadtorenalfailure.Unfortunately,despiteseveral
years of intense investigations and significant advances in medicine
andtherapeutics,therearestillnoeffectivetreatmentsforsepticAKI.
Experimental endotoxemia induced by LPS, the major
endotoxin of gram negative bacteria, is the most frequently
employed model to study septic AKI (LPS-induced AKI). This
model produces consistent renal tissue damage that is similar to
that observed in humans [6–9]. Lipopolysaccharide (LPS)
disseminates to the kidney proximal tubules and microvilli of the
brush border, and is found associated with epithelial cells and
endothelial cells of the peritubular capillaries [10]. Localized LPS
promotes TNFa production by resident renal tubular epithelial
cells [11], mesangial cells [12], glomerular cells [13], as well as
leukocytes which adhere to the endothelium [12]. Thus, renal
TNFa is proposed to be responsible for some of the renal
dysfunction observed in LPS-induced AKI [6;14] through both
direct cellular injury [15] and the amplified induction of localized
inflammatory mediators (via NFkB activation), including cytokines
and chemokines which stimulate the infiltration of damaging
neutrophils and monocytes into the kidneys, particularly the renal
cortex [6]. In addition, extrarenal and systemic TNFa contributes
to kidney injury observed during septic-AKI [7]. Concurrent
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lial cell activation, microvascular injury, increased vascular
permeability, intraglomerular thrombosis, and reduced renal
perfusion are typically observed in sepsis-associated AKI [12,16].
Because the pathogenesis of sepsis-associated AKI is ultimately
mediated through multiple pathways, a multi-targeted therapeutic
approach is warranted. One recently described broad-based
physiologic mechanism for regulating inflammation is the
cholinergic anti-inflammatory pathway [17]. This pathway can
be stimulated by the administration of nicotinic acetylcholine
receptor (nAChR) agonists, including nicotine and GTS-21, to
produce beneficial anti-inflammatory effects [18–22], even in the
absence of an intact vagus nerve [23]. Recent studies show that
nicotinic agonists abrogate renal damage during experimental
ischemia-reperfusion injury [23,24]. While a localized anti-
inflammatory effect was observed, the exact mechanism involved
in mediating the anti-inflammatory effects of nicotinic agonists is
not well understood. We investigated the effect of nicotinic
agonists on renal NFkB and proteasome activity, as well as renal
damage during septic AKI.
Results
Nicotinic Agonists Attenuate LPS-induced AKI
Administration of either nicotine or GTS-21 during LPS-
induced septic AKI model significantly suppressed kidney injury
induced by LPS. Both nicotine and GTS-21 treatment reduced
leukocyte infiltration (assessed by renal myeloperoxidase (MPO)
levels) within the kidney by approximately 40%, during exper-
imental LPS-AKI compared to saline treatment (Fig. 1A).
Consistent with the decline in leukocyte trafficking to the kidneys,
improved renal function (as suggested by BUN levels) was
observed (Fig. 1B).
Nicotinic Agonists Regulate Systemic and Renal
Inflammation During LPS-induced AKI
LPS produces renal damage by directly stimulating TNFa
production within the kidney [6,11–13] and by increasing
circulating TNFa levels [7]. Serum TNFa levels were enhanced
during LPS-AKI and treatment with nicotinic agonists reduced
serum TNFa levels (Fig. 2A). In addition, septic AKI was
accompanied by significant kidney inflammation as measured by
kidney TNFa, CCL2, and CXCL10 levels (Figs. 2B–D); renal
concentrations of these pro-inflammatory mediators were blunted
by treatment with nicotinic agonists (Figs. 2B–D).
Chemokine Production by Human Kidney Cells is
Reduced by Nicotinic Agonists
To determine the potential cellular targets of nicotinic agonists
within the kidney we examined the effect of nicotine and GTS-
21 on both LPS- and TNFa-induced pro-inflammatory mediator
production by several kidney cell populations, including human
renal proximal tubular epithelial cells (HK-2 cells), human renal
glomerular endothelial cells (HRGECs), and human mesangial
cells (HMCs) (Fig. 3A–C). Stimulation with LPS induced
significant production of CXCL8 by HK-2 cells, HRGECs,
and HMCs, CXCL10 by HRGECs, and CCL2 by HRGECs
and HMCs (Fig. 3). TNFa treatment induced significant
production of both CXCL8 and CCL2 by HK-2 cells, HRGECs,
and HMCs, and CXCL10 by HMCs (Fig. 3). Treatment of HK-
2 cells with nicotinic agonists significantly reduced both LPS- and
TNFa-induced CXCL8 and TNFa-induced CCL2 (Fig. 3A). We
observed that treatment of HRGECs with either nicotine or
GTS-21 (at optimal concentrations) significantly blocked LPS-
induced CXCL8, CXCL10, and CCL2 production (Fig. 3B) and
TNFa-induced CXCL8 and CCL2 production (Fig. 3B). Treat-
ment of HMCs with nicotinic agonists significantly suppressed
LPS-induced CXCL8 and CCL2 production (Fig. 3C) and
TNFa-induced CXCL8, CXCL10, and CCL2 production
(Fig. 3C). As expected, Bay 11, a cell-permeable inhibitor of
IkBa phosphorylation and hence, inhibitor of NFkB activation,
significantly reduced LPS- and TNFa-induced chemokine pro-
duction by all three cell types (Fig. 3A–C). Treatment of
HRGECs and HMCs with abungarotoxin (aBGT), an
a7nAChR selective antagonist, prior to nicotinic agonists partly
reversed their inhibitory effects on TNF- and LPS-induced
CCL2 production (Fig. 3D).
Kidney Cells Express a4, a7, and b2 nAChR Subunits
While nicotine is a non-specific nAChR agonist, GTS-21 is
a partial selective agonist of the a7nAChR but can also bind to
a4b2nAChRs. Using QPCR methods we detected the presence
of a7, a4, and b2 nAChR subunits in normal mouse kidneys.
When expressed as a ratio of specific nAChR subunit
mRNA:HPRT1 (housekeeping gene) mRNA, a4, a7, and b2
nAChR subunit expressions were 2.29260.21; 1.62860.054;
1.33460.091, respectively. We used the human kidney cells/cell
lines to explore the expression of these nAChR subunits by
various kidney cell types using flow cytometry methods. All
three cell types expressed all three nAChR subunits, with
a7nAChR expression the highest for both HK-2 (proximal
Figure 1. Nicotinic agonists protect against kidney damage during LPS-induced septic AKI. (A-B) Mice were treated with saline alone or
LPS (5 mg/kg) plus either saline, nicotine (1 mg/kg), or GTS-21 (4 mg/kg, i.p). (A) Renal leukocyte infiltration was determined by measuring kidney
MPO levels by ELISA. (B) BUN levels (mg/dL) were assessed 24 hrs post LPS. Data are shown as mean6SD. *p,0.05, **p,0.001 vs. Sal+LPS-treated
mice. n=5 for saline alone group and n=8 for all other groups.
doi:10.1371/journal.pone.0035361.g001
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thelial cells) (Fig. 4).
Nicotinic Agonists Suppress LPS-induced AKI-associated
NFkB Activation
]NFkB activation within the kidney regulates the production of
numerous pro-inflammatory mediators during septic AKI [25].
Next, we examined the effects of nicotinic agonist administration
on IkBk degradation within the kidney under normal conditions
and during LPS-induced AKI. Nicotine treatment alone (in the
absence of LPS) slightly enhanced renal IkBa levels by 1064.9%
(mean6SD) (not significant); whereas treatment with GTS-21
alone significantly increased renal IkBa expression by 3368.9%
(P,0.05) when compared to saline-treatment alone. LPS-induced
AKI was accompanied by renal IkBa degradation which was
significantly reduced by treatment of mice with nicotinic agonists
(Fig. 5A). Consistent with these observations, LPS treatment
significantly enhanced NFkB activation within the kidney which
was attenuated by treating the mice with nicotinic agonists
(Fig. 5B).
Proteasome Inhibition Suppresses Inflammatory
Mediator Production by Human Kidney Cells
Because NFkB-mediated inflammation is regulated via IkBa
degradation by the ubiquitin-proteasome system, we investigated
the effect of a widely used proteasome inhibitor, MG132, on LPS-
and TNFa-induced chemokine production by various human
kidney cells. Renal epithelial cells, glomerular endothelial cells and
mesangial cells were treated with either vehicle or MG132
(10 mM) prior to LPS (1 mg/ml) or TNFa (10 ng/ml) addition.
After 18 hours, cell supernatants were assayed for CXCL8 and
CCL2 (Fig. 6). Similar to nicotinic agonists and the NFkB
inhibitor, Bay11, MG132 treatment effectively inhibited LPS- and
TNFa-stimulated chemokine production by all three human
kidney cells (Fig. 6).
LPS-AKI is Accompanied by Enhanced Kidney
Proteasome Activity which can be Reversed by Nicotinic
Agonists
Nuclear NFkB translocation leading to the production of
inflammatory mediators depends, in part, on the degradation of
phosphorylated IkBaby the ubiquitin-proteasome system. Because
LPS-AKI is characterized by renal NFkB activation, we compared
the proteasome activity of kidney tissues obtained from LPS-AKI
mice vs. saline-treated (control) mice. LPS-AKI mice exhibited
significantly enhanced renal proteasome activity compared to
saline control mice (Fig. 7A). Using the septic AKI model,
treatment with either nicotine or GTS-21 significantly attenuated
both ATP-independent and ATP-dependent renal proteasome
activity induced by LPS in vivo (Fig. 7A). Next, we examined the
effect of exogenously added nicotinic agonists on renal proteasome
activity ex vivo using renal homogenates. The addition of nicotine
(10
26 M–10
24 M) or GTS-21 (10
27 M–10
25 M) significantly
inhibited renal proteasome activity ex vivo in the absence (Fig. 7B)
and presence of ATP (Fig. 7C), supporting a direct inhibitory effect
of nicotinic agonists on renal proteasome activity.
Discussion
The prevalence of AKI during sepsis (septic-AKI) significantly
increases during the progression of sepsis with 19%, 23% and 51%
observed among patients with moderate sepsis, severe sepsis, and
septic shock, respectively (Reviewed in [1]). Among hospitalized
patients, the mortality in patients with AKI complicating severe
sepsis is an abysmal 70% compared to 39% in patients with non-
septic AKI [26]. Unfortunately, there is no treatment for AKI or
septic-AKI other than supportive care and treatment of the
underlying disorders. Because nicotinic agonists exert beneficial
anti-inflammatory activity [18–22], we examined the effects of
nicotinic agonist treatment during experimental LPS-induced
septic AKI. We found that administration of nicotine or GTS-21
Figure 2. Nicotinic agonist administration reduces systemic and local renal inflammation during septic AKI. Mice were treated with
saline alone (Sal, i.p.) or LPS (5 mg/kg, i.p.) plus either saline (i.p.), nicotine (Nic, 1 mg/kg, i.p.), or GTS-21 (GTS, 4 mg/kg, i.p.). Serum TNFalevels (A) and
renal TNFa, CCL2 and CXCL10 levels (B–D) were determined by ELISA. Data are shown as mean6SD, as pg/ml (A) or corrected for protein
concentration, pg/mg kidney tissue (B-D). *p,0.05, **p,0.001 vs. Sal+LPS-treated mice. n=5 for saline alone group and n=8 for all other groups.
doi:10.1371/journal.pone.0035361.g002
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leukocytes into the kidneys and reduced BUN levels (suggestive of
reduced kidney injury) (Fig. 1). Using the LPS-AKI model and
various human kidney cells we explored the mechanisms by which
nicotinic agonists attenuate septic AKI.
Both LPS and TNFa have been found in the glomeruli of rats
following LPS administration [10,13]. LPS-induced AKI is
characterized by renal damage mediated, in part, through
localized renal TNFa production [6,14] and enhanced circulating
TNFa [27]. TNFa is produced by isolated glomeruli following
treatment with LPS [13], as well as several kidney cell types (e.g.
mesangial and tubular epithelial cells) [11,12]. Local renal TNFa
production promotes cytotoxic and inflammatory responses within
the kidneys that trigger the generation of additional cytotoxic and
chemotactic mediators. Like TNFa, both CCL2 and CXCL10
have been implicated in renal inflammation. Localized CCL2
production activates tubular epithelial cells to promote tubuloin-
terstitial damage and recruits monocytes which further amplify
renal inflammation [28]. CXCL10 is chemotactic for T cells
(which have been found to be important mediators of renal injury
[29,30]) and promotes T cell-endothelial cell interactions [31].
Using the LPS-AKI model, we found that administration of
nicotinic agonists blunted kidney inflammation (e.g. TNFa, CCL2,
and CXCL10, Fig. 2). To explore which kidney cell types might be
targets of nicotinic agonists, we treated human renal tubular
epithelial, glomerular endothelial, and mesangial cells with
nicotinic agonists during LPS or TNFa stimulation ex vivo. HK-2
renal epithelial cells, which retain the phenotypic expression and
functional characteristics of human proximal tubules [32,33],
produced significant amounts of CXCL8, but not CXCL10 or
CCL2 following LPS stimulation; LPS-induced CXCL8 was
significantly reduced by treatment with nicotinic agonists (Fig. 3A).
Likewise, TNFa induced CXCL8 and low levels of CCL2
production by HK-2 cells which were significantly blocked by
nicotinic agonists (Fig. 3A). We found that nicotinic agonists also
significantly suppressed pro-inflammatory chemokine production
Figure 3. Nicotinic agonists suppress inflammatory responses by human kidney cell populations. (A) Human HK-2 renal tubular
epithelial cells, (B) human renal glomerular endothelial cells (HRGECs), and (C) human mesangial cells (HMCs) were treated with either vehicle (solid
bars), Bay 11, an NFkB inhibitor (20 mM, open bars), nicotine (10 mM, speckled bars), or GTS-21 (1 mM, hatched bars) and then either LPS (1 mg/ml), or
TNFa (20 ng/ml). Supernatants (n=3 wells per condition) were analyzed for CXCL8 (upper panel), CXCL10 (middle panel), and CCL2 (lower panel) by
ELISA. Data are shown as cytokine levels (pg/ml) (mean6SEM) of 3 independent experiments. *p,0.05 vs. LPS- or TNFa-treated control (vehicle) cells.
(D) HRGECs and HMCs were treated with saline or aBGT (2 mM) prior to treatment with nicotine (10 mM, speckled bars), or GTS-21 (1 mM, hatched
bars), and then either LPS (1 mg/ml) or TNFa (20 ng/ml) (solid bars), as indicated. Supernatants (n=3 wells per condition) were analyzed for CCL2.
Data are shown as % control with 100% saline+LPS or saline+TNF. *p,0.05 and **p,0.01 comparing 6aBGT.
doi:10.1371/journal.pone.0035361.g003
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LPS or TNFa stimulation (Fig. 3B). Mesangial cells are localized
around the blood vessels of the kidney at the mesangium where
they function like smooth muscle cells to regulate capillary blood
flow. Treatment of mesangial cells with nicotinic agonists
significantly suppressed both LPS- and TNFa-induced inflamma-
tory chemokine production (Fig. 3C). Similar to previous studies
linking the inhibition of NFkB activation to reduced leukocyte
infiltration during sepsis and endotoxic shock [34], we observed
that both TNFa- and LPS-stimulated chemokine production by
renal cells was blocked by the NFkB inhibitor Bay 11 (Fig. 3).
NFkB activation within the kidneys during septic AKI has been
reported [35,36] and appears to play a critical role in the
regulation of numerous pro-inflammatory mediators during
infection and endotoxemia [25], as well as the promotion of
tubular damage in LPS-induced AKI [36]. The IkBa inhibitory
Figure 4. Human Kidney Cells Express nAChR subunits. To assess nAChR protein levels, (A) HK-2, (B) HRGECs, and (C) HMCs were analyzed by
flow cytometry using specific antibodies against the a7nAChR (green, thick solid line), a4nAChR (pink, dotted line), and b2nAChR (blue, thin solid line)
vs. isotype control (shaded plot). Histogram plots (FL-nAChR subunits vs. counts) are shown for each cell type. (D) Graph shows the average
geometric mean MFI (6SD) for each cell type and each nAChR subunit (isotype control=Is; a7nAChR=a7; a4nAChR=a4; and b2nAChR=b2). n=3
samples per each condition and cell type.
doi:10.1371/journal.pone.0035361.g004
Figure 5. Nicotine and GTS-21 treatment inhibits IkBa degradation and NFkB activation within kidneys during septic AKI. Mice were
treated with saline alone (i.p.) or LPS (5 mg/kg, i.p.) plus either saline, nicotine (1 mg/kg, i.p.), or GTS-21 (4 mg/kg, i.p.). Kidney tissues were analyzed
for (A) IkBa degradation and (B) NFkB activation. (A) Cytoplasmic IkBa and GAPDH levels were assessed by Western blotting (representative blot is
shown) and the density of the bands were analyzed. The data are shown as the ratio of IkBa:GAPDH densities. (B) NFkB activation was determined as
described in the Methods section. Data are shown as NFkB activation (expressed as relative light units, RLU)(mean 6 SD). *p,0.05, **p,0.001 vs.
Sal+LPS. n=5 for saline alone group and n=8 for all other groups.
doi:10.1371/journal.pone.0035361.g005
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[37], the major non-lysosomal mechanism responsible for degrad-
ing regulatory cellular proteins, as well as misfolded, damaged,
and/or unnecessary proteins following ubiquitin tagging [38;39].
In the absence of LPS, there was a slight increase in renal IkBa
levels observed following the injection of nicotine alone and
a significant increase in renal IkBa levels following the injection of
GTS-21 alone, suggesting that nicotinic agonists might either
increase renal IkBa expression or prevent its degradation.
Nicotinic agonist administration reduced IkBa degradation within
the kidneys and significantly suppressed renal NFkB activation in
vivo (Fig. 5), supporting the concept that targeting the NFkB
pathway will protect against kidney damage associated with septic-
AKI, as previously described [40,41]. While skeletal muscle
biopsies obtained from hospitalized patients with sepsis and
multiple organ failure exhibit increased proteasome activity
compared to healthy controls [42], the assessment of kidney
proteasome activity during septic AKI has not been reported.
Treatment of several human kidney cells, including tubular
epithelial cells, endothelial cells, and mesangial cells with a widely
known proteasome inhibitor, MG132, suppressed both TNFa-o r
LPS-stimulated chemokine production (Fig. 6). In addition, we
found that LPS-induced septic AKI was characterized by
enhanced ATP-independent and ATP-dependent renal protea-
some activity in vivo (Fig. 7A) and this activity was significantly
reduced by nicotinic agonist administration in vivo (Fig. 7A).
Likewise, renal proteasome activity (ATP-independent and ATP-
dependent) was inhibited by exogenously added nicotine or GTS-
21 (Fig. 7B–C). Thus, our data support the localized regulation of
proteasome inhibition and inflammation by nicotinic agonists.
These findings are consistent with previous findings revealing that
nicotinic agonists suppressed local inflammation in the absence of
an intact vagus nerve [18]. The inhibition of kidney proteasome
activity ex vivo by nicotine and GTS-21 suggests that nicotinic
agonists directly block proteasome activity. Based on the
preservation of the IkBa-NFkB complex via proteasome inhibition
and the subsequent blockade of NFkB-mediated inflammation,
proteasome inhibitors have emerged as potential therapies for
treating several inflammatory conditions, including adjuvant-
induced arthritis [43], acute pancreatitis [44], hypercholesterol-
emia-associated renal disease [45], and endotoxemia lethality
[46,47].
Nicotinic acetylcholine receptors (nAChRs) are comprised of
a12a10, c, d, and e subunits, and b124 subunits. Outside of the
neuromuscular junction nAChRs form heteropentameric recep-
tors comprised of a and b subunits, and homomeric non-b-
receptors comprised of either a7 and a9 subunits [48,49]. Previous
studies by our group have described the constitutive expression of
the a2, a3, a5, a7, a9, a10, b1, b2 and b4 nAChR subunits in rat
kidney [50]. Using immunohistochemical staining methods, we
showed that the rat kidneys express the a2, a3, and a7 nAChR
subunits (with endothelial cells specifically expressing the
a7nAChR) [50]. While nicotine can bind to: a2b2, a4b2, a3b2,
a4b4, a2b4, a3b4, and a7 subunits, GTS-21, an a7 selective
partial agonist, binds a7 and a4b2 nAChRs. However, GTS-21
appears to only activate the a7nAChRs [51]. In addition, GTS-21
has higher efficacy for rodent a7nAChRs than human a7nAChRs
[52]. Based on our results, we evaluated the expression of the a7,
a4, and b2 subunits in mouse kidneys and human renal cells.
Mouse kidneys express mRNA transcripts for the a7, a4, and b2
nAChR subunits. In addition, we examined the expression of
nAChR by the human kidney cells used in this study. While all
three cell types expressed the a7, a4, and b2 nAChR subunits,
both HK-2 cells (human proximal tubular epithelial cell line) and
HRGECs expressed the highest level of a7nAChR (Fig. 4). From
these results, we demonstrate the expression of the a7nAChR (a
homopentameric receptor), but it is difficult to confirm expression
of the a4b2nAChR by these cells because the a4 and b2 subunits
can form heteropentameric nAChRs with various b subunits and
a subunits, respectively. Treatment of HRGECs and HMCs with
aBGT, an a7nAChR selective antagonist, prior to treatment with
nicotinic agonists significantly blocked their inhibitory effects on
TNF- and LPS-induced CCL2 production (Fig. 3D), supporting
the role of a7nAChRs in mediating the anti-inflammatory effects
of nicotine and GTS-21.
Proteasomes are very large protein complexes composed of
a core of stacked rings (20 S proteasome) flanked by regulatory
particles that facilitate protein entry into the ‘degradation
chamber’ [53]. The complexity of proteasomes implies potentially
multiple mechanisms for their functional regulation. Drews et al
demonstrated that the regulation of cardiac proteasomes involved
Figure 6. Proteasome inhibition blunts inflammatory responses by human kidney cell populations. (A) Human HK-2 renal tubular
epithelial cells, (B) human renal glomerular endothelial cells (HRGECs), and (C) human mesangial cells (HMCs) were treated with either vehicle (filled
bars) or proteasome inhibitor MG132 (10 mM, open bars) and then either LPS (1 mg/ml), or TNFa (20 ng/ml). Cell-free supernatants were analyzed for
CXCL8 (upper panel) or CCL2 (lower panel) by ELISA 18 hrs later. Data are shown as cytokine levels (pg/ml) (mean6SEM) of 3 independent
experiments. *p,0.05, **p,0.001 vs. LPS- or TNFa-treated (vehicle) cells.
doi:10.1371/journal.pone.0035361.g006
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beta adrenergic pathway [54]. Interestingly, previous studies
support the negative regulation of proteolysis by the cholinergic
neurotransmitter acetylcholine. Blockade of acetylcholine release
increased protein degradation by proteasomes in C. elegans while
stimulation of post-synaptic nAChRs via acetylcholine suppressed
proteolysis [55]. Similarly, nicotine-mediated proteasome inhibi-
tion in the brain (in vivo and ex vivo) has been reported. Rezvani and
co-workers found that nicotine treatment reduced proteasome
activity (by directly interacting with the 20 S proteasome), thereby
affecting synaptic plasticity [56]. Together, these data support the
hypothesis that neural cholinergic inputs (e.g. acetylcholine) and
nicotinic agonists regulate proteasome activity by interacting
(either directly or indirectly) with one or more components of the
proteasome complex. Based on our data supporting the role of
a7nAChRs, we postulate that increased intracellular cAMP levels
following a7nAChR ligation [57] augments IkBa levels to
effectively reduce NFkB activation [58–60]. Consistent with this
concept, our data show that in the kidney, nicotinic agonists
increase the cytosolic availability IkBa protein and attenuate
NFkB activation by inhibiting proteasomal degradation of IkBa.
Future studies will investigate the potential mechanism(s) whereby
nicotinic agonists and acetylcholine produced by electrical
stimulation of the vagus nerve lead to the inhibition of proteasome
activity.
In summary, previous studies highlight the broad-based
therapeutic targeting of inflammation using nicotinic agonists via
the regulation of NFkB activation [18,21] (and Fig. 5) and STAT3
activation [50,61]. Herein we demonstrate the suppression of LPS-
and TNFa-induced inflammatory mediator production by resident
kidney cells by nicotinic agonists, enhanced renal proteasome
activity during LPS-AKI, and the attenuation of renal injury in
LPS-induced AKI following treatment with nicotinic agonists
(which suppressed both ATP-dependent and ATP-independent
proteasome activity). Together, these studies support targeting
multiple pathways of inflammation and proteasome activity using
nicotinic agonists to protect against renal inflammation and injury
observed during septic AKI.
Materials and Methods
Antibodies and Reagents
Anti-IkBa and GAPDH antibodies were purchased from Cell
Signaling Technology (Danvers, MA). The a7nAChR (319) and
a4nAChR (286) monoclonal antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), and the b2nAChR
(270) monoclonal antibody was purchased from Covance
(Princeton, NJ). LPS (E. coli 011:B5), nicotine, and ATP were
purchased from Sigma-Aldrich (St. Louis, MO). abungarotoxin
(aBGT) was purchased from Tocris (Minneapolis, MN) and Bay
11-7082 (Bay 11), an NFkB inhibitor, and MG132, a proteasome
inhibitor, were purchased from Calbiochem (San Diego, CA).
GTS-21 was provided by Dr. Y Al-Abed (The Feinstein Institute);
GTS-21 was synthesized as described previously by a reaction of
anabaseine dihydrochloride with 2,4-dimethoxybenzaldehyde
according to [62] and confirmed using NMR and LC-MS
analyses. Suc-LLVY-AMC was purchased from Enzo Life Science
(Farmingdale, NY). Lactacystin was purchased from Boston
Biochemical (Cambridge, MA).
Cell cultures. HK-2 (human renal proximal epithelial
tubule) cells, purchased from ATCC (Manassas, VA), were
grown in DMEM 10%FBS, penicillin, streptomycin, and
glutamine. Normal human mesangial cells (HMCs) (Sciencell,
Carlsbad, CA) and human renal glomerular endothelial cells
(HRGECs) (Sciencell) were grown according to the manufacturers’
recommendations. For activation assays, cells were grown to
confluency in 96-well plates and treated with vehicle or nicotinic
agonists (used at optimal doses determined from our previous
studies [61] or NFkB inhibitor Bay 11 (25mM or MG132 (10 mM)
for 30–45 min prior to stimulation with either LPS (1 mg/ml) or
TNFa (20 ng/ml) (n=3 per condition). After a 20 hr incubation
period, cell-free supernatants were collected and assayed for
CXCL8, CCL2, and/or CXCL10 levels by ELISA (R&D
Systems). Each experiment was repeated twice and the
combined data are shown as mean (6SEM). In a separate set of
Figure 7. Septic AKI is characterized by dysregulated renal
proteasome activity which is attenuated by nicotinic agonists.
(A) Nicotinic agonist treatments vs. saline+LPS-treatment in vivo: Using
the LPS-AKI model, mice were treated with saline, nicotine (1 mg/kg,
i.p.) or GTS-21 (4 mg/kg, i.p.) (n=5 per group); 1 hr post saline or LPS
treatment, the effect of saline vs. nicotinic agonist treatment on LPS-
induced renal proteasome activity (6ATP, 38 mM) was determined.
*p,0.05 vs. Sal+LPS. (B-C) Nicotinic agonist treatments vs. saline
treatment ex vivo: The effects of nicotine and GTS-21 (at the indicated
molar concentrations) vs. saline treatment on proteasome activity in the
absence of exogenously added ATP (B) and in the presence of
exogenously added ATP (C) were assessed ex vivo using mouse kidney
homogenates. Each experiment was repeated and the data are shown
as proteasome activity (mean6SD). *p,0.05 and **p,0.01 vs. Sal
(vehicle control).
doi:10.1371/journal.pone.0035361.g007
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(2 mM) for 30 min before the addition of either nicotine (10 mM,
speckled bars), or GTS-21 (1 mM, hatched bars), followed by
stimulation with either LPS (1 mg/ml, solid bar) or TNFa (20 ng/
ml, solid bar) (n=3 per condition). After an overnight stimulation,
cell-free supernatants were analyzed for CCL2, as described
above. Each experiment was repeated twice and the combined
data are shown as mean %control (6SEM), with 100% being
saline+LPS or saline+TNF. For the assessment of nAChR subunit
expression, flow cytometry methods were used to detect the
expression of specific nAChR subunits, as previously described
[63]. Cultured cells were harvested using a non-enzymatic cell
dissociation buffer (Cellstripper, Cellgro, Manassas, VA); all
samples were blocked with 10% serum and then incubated with
primary antibodies specific for a7nAChR (319), a4nAChR (286),
and b2nAChR (270) subunits, according to the manufacturers’
directions. Antibody binding was revealed using biotinylated anti-
rat IgM+IgG (SouthernBiotech, Birmingham, AL), followed by
avidin-FITC (BD Biosciences). Rat Ig specific isotype controls (BD
Biosciences) were used as negative controls and live fluorescent
cells (without debris or aggregates) were analyzed on
a FACSCalibur flow cytometer (BD). Data were analyzed using
CellQuest data. Data are shown for each cell type as raw mean
fluorescence intensity (FL) vs. counts and as the geometric mean
fluorescence intensity or MFI (6SD) for each subunit for n=3
samples.
Animals
Animal protocols were reviewed and approved by the In-
stitutional Animal Care and Use Committee (IACUC) of the
Feinstein Institute for Medical Research prior to experimentation
(IACUC#2005-049). All animals were housed, maintained, and
manipulated according to the guidelines described in the National
Research Council’s Guide for the Care and Use of Laboratory
Animals.
Animal model of LPS-induced AKI. Swiss Webster mice
(female, ages 8–10 wks, Taconic Farms, n=528 per group) were
injected with LPS (5 mg/kg, i.p.) immediately after saline (200 ml,
i.p.), nicotine (1 mg/kg, i.p.), or GTS-21 (4 mg/kg, i.p.). These
doses were based on our previously published studies [22]. Mice
not euthanized prior to 6 hrs were treated with either additional
saline (200 ml, i.p.), nicotine (1 mg/kg, i.p.), or GTS-21 (4 mg/kg,
i.p.) at 6 and 18 hrs post LPS. Mice were euthanized by CO2
asphyxiation at indicated time points following the injection of
LPS. Blood was collected immediately by cardiac puncture and
serum was isolated and assessed for blood urea nitrogen (BUN)
levels (measured by the Core Laboratories of the North Shore-LIJ
Health System) or stored at 280uC. Cortical kidney samples were
collected and either immediately flash-frozen in liquid nitrogen
(cytokine and myeloperoxidase (MPO) assays) or immediately
processed for the isolation of nuclear and cytoplasmic fractions for
NFkB activation studies (see below).
Assessment of Systemic and Renal Inflammation During
LPS-induced AKI
Mouse serum TNFa levels were assessed at 2 hr post LPS
injection and kidney cytokine/chemokine levels were assessed at
3 hrs post LPS. Frozen cortical renal tissue specimens (200 mg)
were homogenized in 200 ml lysis buffer (Tris buffered saline
pH 7.3 containing 0.5%TritonX-100 and protease inhibitor
cocktail) on ice using a Dounce homogenizer; supernatants were
collected after centrifugation. Serum and homogenates (n=528
mice per group) were assayed for cytokines and chemokines by
ELISA and protein levels by BioRad protein assay (assays
performed in triplicate). Data are expressed as mean concentra-
tions adjusted for protein levels.
Analysis of Renal Leukocyte Infiltration During LPS-
induced AKI
Mice were euthanized 3 hr post saline or LPS (in the presence
or absence of nicotinic agonists) for assessment of leukocyte influx
(n=528 per group). Frozen cortical kidney specimens were
assessed for leukocyte infiltration using an ELISA assay for mouse
myeloperoxidase (MPO), according to the manufacturer’s direc-
tions (Cell Sciences, Canton, MA). Briefly, kidney samples (20 mg)
were homogenized on ice in 200 ml lysis buffer (200 mM NaCl,
5 mM EDTA, 10 mM Tris pH 7.4, 10% glycerin, and protease
inhibitor cocktail). After two centrifugation steps, lysates (1:4
dilution) were assessed for MPO levels by ELISA, using a standard
curve ranging from 0–500 ng/ml.
IkBa Assessment and NFkB Activation Studies
Nuclear and cytoplasmic extracts were isolated from fresh
cortical kidney specimens (n=528 mice per group) collected 3 hrs
post saline or LPS treatment (in the presence and absence of
nicotinic agonist administration) using a nuclear extraction kit
(Active Motif, Carlsbad, CA). Nuclear extracts were analyzed for
NFkB activation using the TransAM NFkB p65/NFkB p50
Chemi Transcription Factor Assay Kit (Active Motif), according to
the manufacturer’s instructions. IkBa protein levels (and GAPDH
levels) in the cytoplasmic extracts were determined by Western
blotting using specific anti-IkBa and GAPDH antibodies (a
representative blot is shown). The density of the bands was
determined using the NIH image program and the ratios of
IkBa:GAPDH densities are shown.
Assessment of nAChR mRNA Expression by Mouse
Kidney Tissue Using QPCR
RNA was isolated from 100 mg of normal mouse kidney tissue
using the RNeasyH Mini kit (Qiagen, Valencia CA) with DNase
treatment, according to the manufacturer’s directions. The purity/
concentration of total RNA was assayed using the NanoDrop
spectrophotometer (Wilmington, DE). QPCR was used to assess
specific nAChR mRNA expression using the following primers
(and Roche Universal library probes): a7nAChR: forward: 59-
ccctggctttgctggtatt-39, reverse: 59-gcatgaagacagtcagagaaagtaa-39
(probe 27);a4nAChR: forward: 59-cgtccagtacattgcagacc-39, re-
verse: 59-atggccacgtatttccagtc-39 (probe 29); b2 nAChR: forward:
59-actctatggcgctgctgttc-39, reverse: 59-tcctctgtgtcagtacccaaaa-39
(probe 76); HPRT1 forward: 59-tcctcctcagaccgctttt-39, reverse:
59-cctggttcatcatcgctaatc-39 (probe 95). Briefly, PCR reactions were
performed in quadruplicate using the Eurogentec One step RT
qPCR mastermix, 100 ng RNA and the Roche 480 Light Cycler
using the following conditions: 48uC for 30 min, 95uC for 10 min
followed by 45 cycles of 95uC for 15 secs and 60uC for 1 min.
Relative gene expression was calculated using the comparative Ct
(DDCt) method as target gene to HPRT1 (housekeeping gene) for
normalizing transcript levels [64].
Renal Proteasome Activity Assays
The effect of nicotinic agonists on kidney proteasome activity
was determined using the Suc-LLVY-AMC (chymotrypsin-like)
substrate in the absence and presence of exogenously added ATP,
as previously described [65;66]. For in vivo proteasome inhibition
assays, mice (5 per group) were treated with saline, GTS-21
(4 mg/kg, i.p.) or nicotine (1 mg/kg, i.p.). Cortical kidney sections
were isolated from mice, flash-frozen, and stored at 280uC; frozen
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(50 mM HEPES, pH 7.5, 20 mM KCl, 5 mM MgCl2,1m M
DTT) and used immediately. Briefly, 5 mg kidney homogenates
(per well, with each sample run in triplicate) was incubated with
vehicle or lactacystin (15 mM) for 20 min at RT prior to addition
of assay buffer containing either 0 or 38 mM ATP. The reaction
was initiated with the addition of substrate (Suc-LLVY-AMC) and
incubated for 30 min at 37uC. This concentration of ATP (38 mM)
was chosen because it produced maximal stimulation of protea-
some activity using mouse renal homogenates (5 mg). The assay
was terminated by the addition of 150 ml cold ethanol and read in
a VictorX3 fluorescence plate reader (Perkin Elmer, Ex 360/
Ex440 nm). Proteasome activity (chymotrypsin-like activity in
fluorescence units) produced (6exogenously added ATP) was
derived by subtracting the level of fluorescence obtained within
30 min in the presence of lactacystin from the values obtained
without lactacystin after normalization. For the ex vivo assays,
cortical kidney homogenates (5 mg) were incubated with nicotinic
agonists (as indicated) or lactacystin (15 mM) for 20 min at RT
prior to the addition of ATP (or no ATP) and substrate, as
described above. The data from three separate experiments were
averaged and results are shown as the mean proteasome activity
(6SD).
Statistics
Data are expressed as mean6SD (or 6SEM), as indicated. For
data with multiple comparisons, data were analyzed by one way
ANOVA followed by the Dunnett’s test (to compare each
treatment to control value). When only two samples were
compared, Students t tests were used for single comparisons
between treatment and control. P values ,0.05 were considered
significant.
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